April 9-11, 2019 | San Francisco, CA
www.cbinet.com/formulary
Accumulator programs, state-level copay legislation, formulary exclusions, high-deductible plans, changes in benefit design, NDC blocks, step therapy programs - the challenges continue to arise. This April, the industry comes together to tackle these topics and more at the Formulary, Copay and Access Summit in San Francisco.
Visit www.cbinet.com/formulary for further details and to register. Drug Channels readers will save $300 off the standard rate when they use promo code KRA435 and register prior to March 22nd.*
Download the agenda here and see in-depth coverage on critical issues, such as:
- Explore perspectives on accumulator adjustment programs and identify trends for the future
- Demystify proposed legislations and policies for lower drug prices
- Overcome challenges of high-deductible plans, copay caps and the evolving healthcare landscape
- Gain insight on strategies for fast tracking prior authorization and copay assistance for specialty prescriptions
- Gain insight on key stakeholder challenges to discover new methods for manufacturers to collaborate with payers, pharmacists and physicians to improve patient outcomes
- Develop best practices to communicate with field reps when there are issues with co-pay cards
- Break down rebates and reimbursements and the impact on pricing strategies
Wait a minute – we almost forgot the most exciting part! On April 9th, benefit from a pre-conference workshop on Copay Accumulator Programs, where experts in the field will discuss navigating the complexities and impact of the emerging cost-shifting benefit design. You can tack this workshop on to your Formulary Summit registration, or just attend the workshop itself. Learn more here.
CBI will see you there!
*Cannot be combined with other offers or used towards a current registration. Cannot be combined with special category rates, clinic/hospital rates, non-profit rates other offers. Other restrictions may apply.
The content of Sponsored Posts does not necessarily reflect the views of Pembroke Consulting, Inc., Drug Channels, or any of its employees.